Intranasal foralumab can modulate a number of immune cell types in people with non-active SPMS, developer Tiziana Life ...

Susie Wyss used to inject herself daily with a medication for multiple sclerosis. “The injection hurt. It caused welts, ...

The menopausal transition may represent an inflection point for worsening of multiple sclerosis in women, according to study findings.

The incidence of mental illness was higher among women with MS during both the prenatal period (incidence ratio [IR] 1.26, 95 ...

Ozanimod▼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active ...

NEWTOWN, PA — Helius Medical Technologies, Inc. (Nasdaq: HSDT) has announced promising results from its PoNS Therapeutic Experience Program (PoNSTEP), demonstrating the effectiveness of its PoNS ...

MS patients who achieve long-term stable disease on disease-modifying therapy may want to stop their medication for varying ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

The study identified gene expression changes which were detected beginning three months after intranasal dosing of foralumab in our ongoing ISPPEA (or expanded access program). Key findings include ...

Tiziana Life Sciences (TLSA) announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple ...

The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...

PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis-- ...